Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape

Published:2022-02-10 Issue:7 Volume:21 Page:482-483
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Upadhaya Samik,Neftelinov Svetoslav T.,Hodge Jeffrey,Campbell Jay

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.nature.com/articles/d41573-022-00030-4.pdf

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors;European Journal of Medicinal Chemistry;2024-10

2. Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders;Advanced Science;2024-09-09

3. Multi-omics analysis reveals the landscape of tumor microenvironments in left-sided and right-sided colon cancer;Frontiers in Medicine;2024-08-29

4. Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer;JAMA Oncology;2024-08-29

5. ROS-responsive TLR7/8 nanoagonist and ultrasound modulate dendritic cells antigen presentation;Nano Today;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP